##### Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

|    |  |                                                                                        
|--- |  | ---------------------------------------------------------------------------------------
|    |  |                                                                                        
|[X] |  | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|    |  | For the quarterly period ended June 30, 2002                                           

OR

|      |  |                                                                                         
|----- |  | ----------------------------------------------------------------------------------------
|[   ] |  | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|      |  | For the transition period from  to                                                      

Commission file number: 0-19825

SCICLONE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)


|                                                               |  |                                     
|-------------------------------------------------------------- |  | ------------------------------------
|California                                                     |  | 94-3116852                          
|                                                               |  |                                     
|(State or other jurisdiction of incorporation or organization) |  | (I.R.S. employer
Identification no.)
|                                                               |  |                                     
|901 Mariners Island Blvd., Suite 205, San Mateo, California   |  | 94404                               
|                                                               |  |                                     
|(Address of principal executive offices)                       |  | (Zip code)                          

(650) 358-3456
(Registrants telephone number, including area code)

Not Applicable
(Former name, former address and former fiscal year, if changed since last
report)

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

Yes [X]      No [   ]

As of June 30, 2002, 36,854,055 shares of the registrants Common Stock,
no par value, were issued and outstanding.





---

TABLE OF CONTENTS



|                                              |                                                                                               |                                                      |  |  |  |  |  | 
|--------------------------------------------- | --------------------------------------------------------------------------------------------- | ---------------------------------------------------- |  |  |  |  |  | 
|PART I. FINANCIAL INFORMATION                
|                                              | Item 1. Condensed Consolidated Financial Statements                                          
|                                              |                                                                                               | CONDENSED CONSOLIDATED BALANCE SHEETS               
|                                              |                                                                                               | CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS     
|                                              |                                                                                               | CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS     
|                                              |                                                                                               | Notes to Condensed Consolidated Financial Statements
|                                              | Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations
|                                              | Item 3. Quantitative and Qualitative Disclosures About Market Risk.                          
|PART II. OTHER INFORMATION                   
|                                              | Item 4. Submission of Matters to a Vote of Security Holders                                  
|                                              | Item 6. Exhibits and Reports on Form 8-K                                                     
|SIGNATURES                                   
|Section 906 of the Sarbanes-Oxley Act of 2002
|Section 906 of the Sarbanes-Oxley Act of 2002



---



##### Table of Contents



SCICLONE PHARMACEUTICALS, INC.

INDEX

|           |  |                                                                                                                        |  |         
|---------- |  | ---------------------------------------------------------------------------------------------------------------------- |  | --------
|           |  |                                                                                                                        |  | PAGE NO.
|           |  |                                                                                                                        |  |         
|PART I.    |  | FINANCIAL INFORMATION                                                                                                  |  |         
|Item 1.    |  | Condensed Consolidated Financial Statements (Unaudited)                                                                |  |         
|           |  | Condensed Consolidated Balance Sheets as of June 30, 2002
and December 31, 2001                                        |  | 3       
|           |  | Condensed Consolidated Statements of Operations for the
Three-month and Six-month periods ended June 30, 2002 and
2001 |  | 4       
|           |  | Condensed Consolidated Statements of Cash Flows for the
Six-month periods ended June 30, 2002 and 2001                 |  | 5       
|           |  | Notes to Condensed Consolidated Financial Statements                                                                   |  | 6       
|Item 2.    |  | Managements Discussion and Analysis of Financial
Condition and Results of Operations                                  |  | 9       
|Item 3.    |  | Quantitative and Qualitative Disclosures About Market Risk                                                             |  | 24      
|          
|PART II.   |  | OTHER INFORMATION                                                                                                      |  |         
|Item 4.    |  | Submission of Matters to a Vote of Security Holders                                                                    |  | 25      
|Item 6.    |  | Exhibits and Reports on Form 8-K                                                                                       |  | 26      
|Signatures |  |                                                                                                                        |  | 27      

2



---



##### Table of Contents






PART I. FINANCIAL INFORMATION




Item 1. Condensed Consolidated Financial Statements




SCICLONE PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

ASSETS

|                                           |                                                                                                                                                                        |   |             |              |              |   |            |              |  
|------------------------------------------ | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- | - | ----------- | ------------ | ------------ | - | ---------- | ------------ | -
|                                           |                                                                                                                                                                        |   | June 30,    |              | December 31,
|                                           |                                                                                                                                                                        |   | 2002        |              | 2001        
|                                           |                                                                                                                                                                        |   |             |              |             
|                                           |                                                                                                                                                                        |   | (unaudited) |              | (Note 1)    
|Current assets:                            |                                                                                                                                                                        |   |             |              |              |   |            |             
|                                           | Cash and cash equivalents                                                                                                                                              |   | $           | 23,421,000   |              |   | $          | 15,518,000   |  
|                                           | Restricted short-term investments                                                                                                                                      |   |             | 633,000      |              |   |            | 633,000      |  
|                                           | Other short-term investments                                                                                                                                           |   |             | 346,000      |              |   |            | 317,000      |  
|                                           | Accounts receivable, net                                                                                                                                               |   |             | 9,659,000    |              |   |            | 8,792,000    |  
|                                           | Inventories                                                                                                                                                            |   |             | 3,895,000    |              |   |            | 4,059,000    |  
|                                           | Prepaid expenses and other current assets                                                                                                                              |   |             | 556,000      |              |   |            | 1,333,000    |  
|                                           |                                                                                                                                                                        |   |             |              |              |   |            |             
|Total current assets                       |                                                                                                                                                                        |   | 38,510,000  |              |              |   | 30,652,000 |             
|Property and equipment, net                |                                                                                                                                                                        |   | 135,000     |              |              |   | 167,000    |             
|Intangible assets, net                     |                                                                                                                                                                        |   | 887,000     |              |              |   | 1,091,000  |             
|Other assets                               |                                                                                                                                                                        |   | 175,000     |              |              |   | 186,000    |             
|                                           |                                                                                                                                                                        |   |             |              |              |   |            |             
|Total assets                               |                                                                                                                                                                        | $ | 39,707,000  |              |              | $ | 32,096,000 |             
|                                           |                                                                                                                                                                        |   |             |              |              |   |            |             
|                                          
|LIABILITIES AND SHAREHOLDERS EQUITY      
|Current liabilities:                       |                                                                                                                                                                        |   |             |              |              |   |            |             
|                                           | Accounts payable                                                                                                                                                       |   | $           | 1,473,000    |              |   | $          | 1,575,000    |  
|                                           | Accrued compensation and employee benefits                                                                                                                             |   |             | 662,000      |              |   |            | 960,000      |  
|                                           | Accrued clinical trials expense                                                                                                                                        |   |             | 1,113,000    |              |   |            | 296,000      |  
|                                           | Accrued professional fees                                                                                                                                              |   |             | 615,000      |              |   |            | 633,000      |  
|                                           | Deferred revenue                                                                                                                                                       |   |             | 895,000      |              |   |            |             |  
|                                           | Other accrued expenses                                                                                                                                                 |   |             | 209,000      |              |   |            | 258,000      |  
|                                           |                                                                                                                                                                        |   |             |              |              |   |            |             
|Total current liabilities                  |                                                                                                                                                                        |   | 4,967,000   |              |              |   | 3,722,000  |             
|Deferred revenue                           |                                                                                                                                                                        |   | 1,566,000   |              |              |   |           |             
|Convertible notes payable                  |                                                                                                                                                                        |   | 5,600,000   |              |              |   | 5,600,000  |             
|Shareholders equity:                      |                                                                                                                                                                        |   |             |              |              |   |            |             
|                                           | Common stock, no par value; 75,000,000
shares authorized; 36,854,055 and
32,474,150 shares issued and outstanding
at June 30, 2002 and December 31, 2001,
respectively |   |             | 156,238,000  |              |   |            | 145,713,000  |  
|                                           | Accumulated other comprehensive income                                                                                                                                 |   |             | 63,000       |              |   |            | 39,000       |  
|                                           | Accumulated deficit                                                                                                                                                    |   |             | (128,727,000 | )            |   |            | (122,978,000 | )
|                                           |                                                                                                                                                                        |   |             |              |              |   |            |             
|Total shareholders equity                 |                                                                                                                                                                        |   | 27,574,000  |              |              |   | 22,774,000 |             
|                                           |                                                                                                                                                                        |   |             |              |              |   |            |             
|Total liabilities and shareholders equity |                                                                                                                                                                        | $ | 39,707,000  |              |              | $ | 32,096,000 |             
|                                           |                                                                                                                                                                        |   |             |              |              |   |            |             

See notes to condensed consolidated financial statements

3



---



##### Table of Contents






SCICLONE PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

|                                                                              |                            |   |                    |           |                  |   |            |           |      |   |            |           |  |   |            |           | 
|----------------------------------------------------------------------------- | -------------------------- | - | ------------------ | --------- | ---------------- | - | ---------- | --------- | ---- | - | ---------- | --------- |  | - | ---------- | --------- | 
|                                                                              |                            |   | Three months ended |           | Six months ended
|                                                                              |                            |   | June 30,           |           | June 30,        
|                                                                              |                            |   |                    |           |                 
|                                                                              |                            |   | 2002               |           | 2001             |   | 2002       |           | 2001
|                                                                              |                            |   |                    |           |                  |   |            |           |     
|Product sales                                                                 |                            | $ | 4,048,000          |           |                  | $ | 3,250,000  |           |      | $ | 7,996,000  |           |  | $ | 6,363,000  |          
|Contract revenue                                                              |                            |   | 224,000            |           |                  |   |           |           |      |   | 224,000    |           |  |   |           |          
|                                                                              |                            |   |                    |           |                  |   |            |           |      |   |            |           |  |   |            |          
|Total revenue                                                                 |                            |   | 4,272,000          |           |                  |   | 3,250,000  |           |      |   | 8,220,000  |           |  |   | 6,363,000  |          
|Cost of product sales                                                         |                            |   | 815,000            |           |                  |   | 636,000    |           |      |   | 1,607,000  |           |  |   | 1,234,000  |          
|                                                                              |                            |   |                    |           |                  |   |            |           |      |   |            |           |  |   |            |          
|Gross profit                                                                  |                            |   | 3,457,000          |           |                  |   | 2,614,000  |           |      |   | 6,613,000  |           |  |   | 5,129,000  |          
|Operating expenses:                                                           |                            |   |                    |           |                  |   |            |           |      |   |            |           |  |   |            |          
|                                                                              | Research and development   |   |                    | 3,771,000 |                  |   |            | 1,586,000 |      |   |            | 6,297,000 |  |   |            | 3,327,000 | 
|                                                                              | Sales and marketing        |   |                    | 2,066,000 |                  |   |            | 2,651,000 |      |   |            | 4,074,000 |  |   |            | 4,928,000 | 
|                                                                              | General and administrative |   |                    | 955,000   |                  |   |            | 961,000   |      |   |            | 1,947,000 |  |   |            | 1,791,000 | 
|                                                                              |                            |   |                    |           |                  |   |            |           |      |   |            |           |  |   |            |          
|Total operating expenses                                                      |                            |   | 6,792,000          |           |                  |   | 5,198,000  |           |      |   | 12,318,000 |           |  |   | 10,046,000 |          
|                                                                              |                            |   |                    |           |                  |   |            |           |      |   |            |           |  |   |            |          
|Loss from operations                                                          |                            |   | (3,335,000         | )         |                  |   | (2,584,000 | )         |      |   | (5,705,000 | )         |  |   | (4,917,000 | )        
|Interest and investment income                                                |                            |   | 76,000             |           |                  |   | 221,000    |           |      |   | 152,000    |           |  |   | 484,000    |          
|Interest and investment expense                                               |                            |   | (90,000            | )         |                  |   | (90,000    | )         |      |   | (180,000   | )         |  |   | (153,000   | )        
|Other income (expense), net                                                   |                            |   | 4,000              |           |                  |   | 234,000    |           |      |   | (15,000    | )         |  |   | 242,000    |          
|                                                                              |                            |   |                    |           |                  |   |            |           |      |   |            |           |  |   |            |          
|Net loss                                                                      |                            | $ | (3,345,000         | )         |                  | $ | (2,219,000 | )         |      | $ | (5,748,000 | )         |  | $ | (4,344,000 | )        
|                                                                              |                            |   |                    |           |                  |   |            |           |      |   |            |           |  |   |            |          
|Basic and diluted net loss per share                                          |                            | $ | (0.10              | )         |                  | $ | (0.07      | )         |      | $ | (0.17      | )         |  | $ | (0.13      | )        
|                                                                              |                            |   |                    |           |                  |   |            |           |      |   |            |           |  |   |            |          
|Weighted average
shares used in computingBasic and
diluted net loss per share |                            |   | 33,595,568         |           |                  |   | 32,289,857 |           |      |   | 33,092,358 |           |  |   | 32,266,474 |          
|                                                                              |                            |   |                    |           |                  |   |            |           |      |   |            |           |  |   |            |          

See notes to condensed consolidated financial statements

4



---



##### Table of Contents






SCICLONE PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)

|                                                                            |                                                                |                                             |            |                  |           |      |            |           |          |  
|--------------------------------------------------------------------------- | -------------------------------------------------------------- | ------------------------------------------- | ---------- | ---------------- | --------- | ---- | ---------- | --------- | -------- | -
|                                                                            |                                                                |                                             |            | Six months ended
|                                                                            |                                                                |                                             |            | June 30,        
|                                                                            |                                                                |                                             |            |                 
|                                                                            |                                                                |                                             |            | 2002             |           | 2001
|                                                                            |                                                                |                                             |            |                  |           |     
|Operating activities:                                                       |                                                                |                                             |            |                  |           |      |            |          
|Net loss                                                                    |                                                                | $                                           | (5,748,000 | )                |           | $    | (4,344,000 | )        
|Adjustments to reconcile net loss to net cash used in
operating activities: |                                                                |                                             |            |                  |           |      |            |          
|                                                                            | Depreciation and amortization                                  |                                             |            | 292,000          |           |      |            | 261,000   |         
|                                                                            | Changes in operating assets and liabilities:                   |                                             |            |                  |           |      |            |           |         
|                                                                            |                                                                | Accounts receivable, net                    |            |                  | (867,000  | )    |            |           | 687,000  |  
|                                                                            |                                                                | Inventories                                 |            |                  | 164,000   |      |            |           | (276,000 | )
|                                                                            |                                                                | Prepaid expenses and other current assets   |            |                  | 777,000   |      |            |           | (877,000 | )
|                                                                            |                                                                | Accounts payable and other accrued expenses |            |                  | (151,000  | )    |            |           | (232,000 | )
|                                                                            |                                                                | Accrued compensation and employee benefits  |            |                  | (298,000  | )    |            |           | (235,000 | )
|                                                                            |                                                                | Accrued clinical trials expense             |            |                  | 817,000   |      |            |           | 38,000   |  
|                                                                            |                                                                | Accrued professional fees                   |            |                  | (18,000   | )    |            |           | 327,000  |  
|                                                                            |                                                                | Deferred revenue                            |            |                  | 2,461,000 |      |            |           |         |  
|                                                                            |                                                                |                                             |            |                  |           |      |            |          
|Net cash used in operating activities                                       |                                                                |                                             | (2,571,000 | )                |           |      | (4,651,000 | )        
|                                                                            |                                                                |                                             |            |                  |           |      |            |          
|Investing activities:                                                       |                                                                |                                             |            |                  |           |      |            |          
|                                                                            | Purchase of property and equipment                             |                                             |            | (43,000          | )         |      |            | (28,000   | )       
|                                                                            | Payment on purchase of marketable securities                   |                                             |            | (7,000           | )         |      |            | (316,000  | )       
|                                                                            |                                                                |                                             |            |                  |           |      |            |          
|Net cash used in investing activities                                       |                                                                |                                             | (50,000    | )                |           |      | (344,000   | )        
|                                                                            |                                                                |                                             |            |                  |           |      |            |          
|Financing activities:                                                       |                                                                |                                             |            |                  |           |      |            |          
|                                                                            | Proceeds from issuance of convertible note                     |                                             |            |                 |           |      |            | 1,600,000 |         
|                                                                            | Proceeds from issuance of common stock, net of
financing costs |                                             |            | 10,524,000       |           |      |            | 720,000   |         
|                                                                            |                                                                |                                             |            |                  |           |      |            |          
|Net cash provided by financing activities                                   |                                                                |                                             | 10,524,000 |                  |           |      | 2,320,000  |          
|                                                                            |                                                                |                                             |            |                  |           |      |            |          
|Net increase (decrease) in cash and cash equivalents                        |                                                                |                                             | 7,903,000  |                  |           |      | (2,675,000 | )        
|Cash and cash equivalents, beginning of period                              |                                                                |                                             | 15,518,000 |                  |           |      | 21,981,000 |          
|                                                                            |                                                                |                                             |            |                  |           |      |            |          
|Cash and cash equivalents, end of period                                    |                                                                | $                                           | 23,421,000 |                  |           | $    | 19,306,000 |          
|                                                                            |                                                                |                                             |            |                  |           |      |            |          

See notes to condensed consolidated financial statements

5



---



##### Table of Contents






SCICLONE PHARMACEUTICALS, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)


1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements
have been prepared in conformity with generally accepted accounting
principles consistent with those applied in, and should be read in
conjunction with, the audited financial statements for the year ended
December 31, 2001 included in the Companys Form 10-K as filed with the
Securities and Exchange Commission. The interim financial information
reflects all normal recurring adjustments which are, in the opinion of
management, necessary for a fair presentation of the results for the
interim periods presented and are not necessarily indicative of results
for subsequent interim periods or for the full year. The condensed
consolidated balance sheet data at December 31, 2001 is derived from the
audited financial statements at that date but does not include all of the
information and footnotes required by generally accepted accounting
principles for complete financial statements. Certain prior year amounts
have been reclassified to conform to the current period presentation.

2. Significant Accounting Policies

Revenue Recognition

The Company recognizes revenue from product sales at the time of shipment
and recognizes contract/grant revenue when services have been performed.
There are no significant customer acceptance requirements or post
shipment obligations on the part of the Company. Sales to importing
agents or distributors are recognized at time of shipment when title to
the product is transferred to them, and they do not have contractual
rights of return except under limited terms regarding product quality.
However, the Company will replace products that have expired or are
deemed to be damaged or defective when delivered. Payments by the
importing agents and distributors are not contingent upon sale to the end
user by the importing agents or distributors. Contract revenue for
research and development is recorded as earned based on the performance
requirements of the contract. Nonrefundable contract fees for which no
further performance obligations exist, and there is no continuing
involvement by the Company, are recognized on the earlier of when the
payments are received or when collection is assured. Revenue associated
with substantive performance milestones is recognized based upon the
achievement of the milestones, as defined in the respective agreements.
Revenue under research and development cost reimbursement contracts is
recognized as the related costs are incurred.

Net Loss Per Share

Net loss per share is computed using the weighted
average number of shares of common stock outstanding. Common equivalent shares from stock
options and warrants are excluded, as their effect is antidilutive.

6



---



##### Table of Contents



Recent Accounting Pronouncements

The Company adopted Financial Accounting Standards Board Statement of
Financial Accounting Standards No. 142, Goodwill and Other Intangible
Assets, on January 1, 2002. There has been no impact on the Companys
operating results from the adoption of this standard.

3. Comprehensive Loss

For the three-month periods ended June 30, 2002 and 2001, the Companys
total comprehensive loss amounted to $(3,359,000) and $(2,168,000),
respectively. For the six-month periods ended June 30, 2002 and 2001, the
Companys total comprehensive loss amounted to $(5,724,000) and
$(4,280,000), respectively.

4. Available-For-Sale Securities

The following is a summary of available-for sale securities at June 30,
2002 and December 31, 2001:

|                   |                             |   |            |            |            |   |        |        |           |   |            |            | 
|------------------ | --------------------------- | - | ---------- | ---------- | ---------- | - | ------ | ------ | --------- | - | ---------- | ---------- | 
|                   |                             |   |            |            |            |   | Gross  |        | Estimated
|                   |                             |   | Amortized  |            | Unrealized |   | Fair  
|                   |                             |   | Cost       |            | Gains      |   | Value 
|                   |                             |   |            |            |            |   |       
|June 30, 2002:     |                             |   |            |            |            |   |        |        |           |   |            |           
|                   | Certificate of deposit      |   | $          | 867,000    |            |   | $      |       |           |   | $          | 867,000    | 
|                   | Corporate obligations       |   |            | 19,778,000 |            |   |        | 1,000  |           |   |            | 19,779,000 | 
|                   | Corporate equity securities |   |            | 51,000     |            |   |        | 61,000 |           |   |            | 112,000    | 
|                   |                             |   |            |            |            |   |        |        |           |   |            |           
|                   |                             | $ | 20,696,000 |            |            | $ | 62,000 |        |           | $ | 20,758,000 |           
|                   |                             |   |            |            |            |   |        |        |           |   |            |            | 
|December 31, 2001: |                             |   |            |            |            |   |        |        |           |   |            |           
|                   | Certificate of deposit      |   | $          | 865,000    |            |   | $      |       |           |   | $          | 865,000    | 
|                   | Corporate obligations       |   |            | 10,858,000 |            |   |        | 6,000  |           |   |            | 10,864,000 | 
|                   | Corporate equity securities |   |            | 51,000     |            |   |        | 33,000 |           |   |            | 84,000     | 
|                   |                             |   |            |            |            |   |        |        |           |   |            |           
|                   |                             | $ | 11,774,000 |            |            | $ | 39,000 |        |           | $ | 11,813,000 |           
|                   |                             |   |            |            |            |   |        |        |           |   |            |            | 

As of June 30, 2002, the total available-for-sale securities are included
as follows, $19,779,000 in cash and cash equivalents, $633,000 in
restricted short-term investments and $346,000 in other short-term
investments.

5. Inventories

The following is a summary of inventories at June 30, 2002 and December
31, 2001:

|                 |  |          |           |              |  |   |           |  
|---------------- |  | -------- | --------- | ------------ |  | - | --------- | -
|                 |  | June 30, |           | December 31,
|                 |  | 2002     |           | 2001        
|                 |  |          |           |             
|Raw materials    |  | $        | 2,768,000 |              |  | $ | 2,759,000 |  
|Work in progress |  |          | 637,000   |              |  |   | 1,269,000 |  
|Finished goods   |  |          | 625,000   |              |  |   | 431,000   |  
|Reserve          |  |          | (135,000  | )            |  |   | (400,000  | )
|                 |  |          |           |              |  |   |           |  
|                 |  | $        | 3,895,000 |              |  | $ | 4,059,000 |  
|                 |  |          |           |              |  |   |           |  

7



---



##### Table of Contents



6. Intangible Assets

The following is a summary of intangible assets at June 30, 2002 and
December 31, 2001:

|                          |  |          |            |              |  |   |            |  
|------------------------- |  | -------- | ---------- | ------------ |  | - | ---------- | -
|                          |  | June 30, |            | December 31,
|                          |  | 2002     |            | 2001        
|                          |  |          |            |             
|Intangible product rights |  | $        | 2,456,000  |              |  | $ | 2,456,000  |  
|Accumulated amortization  |  |          | (1,569,000 | )            |  |   | (1,365,000 | )
|                          |  |          |            |              |  |   |            |  
|                          |  | $        | 887,000    |              |  | $ | 1,091,000  |  
|                          |  |          |            |              |  |   |            |  

ZADAXIN® product rights that the Company acquired are being amortized
over six years beginning in September 1998. Amortization expense for the
three and six month periods ended June 30, 2002 and 2001 was $101,000 and
$204,000, respectively, for both years. Amortization expense for the
years ended December 31, 2002, 2003 and 2004 is expected to be $409,000,
$409,000 and $273,000, respectively. The Company reassesses the useful
life of these assets in accordance with current facts and circumstances.
The Companys policy is to identify and record impairment losses, as
circumstances dictate, on intangible product rights when events and
circumstances indicate that the assets might be impaired and the
undiscounted cash flows estimated to be generated by those assets are
less than the carrying amounts of those assets. The Company to date has
not identified any changes in useful life or impairment losses on these
assets.

7. Shareholders Equity

In June 2002, the Company completed an offering of common stock with
various existing and new institutional investors. The Company raised net
proceeds of $9,959,000 from the offering of 4,088,460 shares of
common stock at $2.60 per share.

8. Minimum Purchase Requirements

The Company does not have any minimum purchase requirements under its
contract manufacturing supply agreements for ZADAXIN and CPX.

9. Deferred Revenue

In January 2002, the Company received $2,685,000 from its European
partner, Sigma-Tau under the terms of our collaborative agreement
announced in late December 2001. This receipt has been recorded as
deferred revenue and will be recognized as contract revenue over the next
three years starting in April 2002, the estimated time to complete the
ZADAXIN hepatitis C U.S. clinical program and anticipated FDA regulatory
filings. For the three-month period ended June 30, 2002, the Company
recognized $224,000 as contract revenue.

8



---



##### Table of Contents






Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations

Special Note Regarding Forward-Looking Statements

This Report contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking statements
are based on our current expectations, estimates and projections about our
industry, managements beliefs and certain assumptions made by us. Words such
as anticipates, expects, intends, plans, believes or similar
expressions are intended to identify forward-looking statements and our forward
looking statements include those statements we make regarding the timing and
outcome of clinical trials, anticipated sales and research and development
expense levels. These statements are not guarantees of future performance and
are subject to certain risks, uncertainties and assumptions that are difficult
to predict. Therefore, our actual results could differ materially and adversely
from those expressed in any forward-looking statements as a result of various
factors including, but not limited to, those described under the caption Risk
Factors in this Form 10-Q. We undertake no obligation to revise or update
publicly any forward-looking statements for any reason.

Overview

SciClone Pharmaceuticals, Inc. (SciClone or the Company) is a
biopharmaceutical company and its lead product ZADAXIN, an Immune System
Enhancer, is in two phase 3 hepatitis C clinical trials in the U.S., a phase 3
hepatitis B clinical trial in Japan, two phase 2 liver cancer trials in the
U.S. and a planned phase 2-3 cancer trial program in Europe. ZADAXIN has been
approved for marketing by the ministries of health in 28 countries and is
marketed in the Peoples Republic of China and selected other countries outside
the U.S. ZADAXIN has been administered to more than 10,000 patients in both
clinical and commercial use, alone and in combination with anti-viral and
anti-cancer drugs, without producing any ZADAXIN related significant side
effects or toxicities.

Results of Operations

Total Revenue

Product sales were $4,048,000 and $7,997,000 for the three-month and
six-month periods ended June 30, 2002, as compared to $3,250,000 and $6,363,000
for the corresponding periods in 2001. The growth was largely due to increased
sales of ZADAXIN to our importers in China.

Contract revenue was $224,000 for both the three-month and six-month
periods ended June 30, 2002 as compared to none in 2001. The contract revenue
we received in 2002 was in connection with funds we received from Sigma-Tau.
These funds have been recorded as deferred revenue and are being recognized as
contract revenue over three years starting in April 2002, the estimated time to
complete the ZADAXIN U.S. hepatitis C clinical trial program and anticipated
FDA regulatory filings.

For the three-month and six-month periods ended June 30, 2002, all of our
product sales were derived from sales of ZADAXIN, and in each period, China
accounted for 87% of this

9



---



##### Table of Contents



revenue. Sales emphasis is concentrated in China because, as our most
developed market, marketing expenditures are more likely to result in sales and
profits compared to newer markets, which require investment and development
spending.

Cost of product sales were $815,000 and $1,608,000 for the three-month and
six-month periods ended June 30, 2002 as compared to $636,000 and $1,234,000
for the corresponding periods in 2001 with the increase being primarily due to
higher product sales. We expect cost of product sales to vary from quarter to
quarter, depending upon the level of ZADAXIN sales, the absorption of fixed
product-related costs, and any charges associated with excess or expiring
finished product inventory.

Research and Development

Research and development expenses were $3,771,000 and 6,298,000 for the
three-month and six-month periods ended June 30, 2002, as compared to
$1,586,000 and $3,327,000 for the corresponding periods in 2001. The increase
was primarily to support our late-stage clinical programs for ZADAXIN in the
U.S. and Japan. The initiation and continuation of ZADAXIN clinical
development programs has had, and will continue to have, the largest and most
significant effect on our research and development expenses and is expected to
require us to seek additional capital resources. Our research and development
spending is focused almost exclusively on ZADAXIN, and we expect this to
continue unless and until we obtain additional resources which could be applied
to our other product candidates. In general, we expect product research and
development expenses to increase in absolute dollars over the next several
years and to vary quarter to quarter as we pursue our strategy of initiating
additional preclinical and clinical trials and testing, acquiring product
rights, and expanding regulatory activities.

Sales and Marketing

Sales and marketing expenses were $2,066,000 and $4,074,000 for the
three-month and six-month periods ended June 30, 2002, as compared to
$2,651,000 and $4,928,000 for the corresponding periods in 2001. The decrease
was related to slightly lower promotional and advertising expenses. We expect
our sales and marketing expenses to vary quarter to quarter and to increase in
the next several years as we expect to expand our commercialization and
marketing efforts and pursue additional strategic collaborations.

General and Administrative

General and administrative expenses were $955,000 and $1,946,000 for the
three-month and six-month periods ended June 30, 2002, as compared to $961,000
and $1,791,000 for the corresponding periods in 2001. In the near term, we
expect general and administrative expenses to vary quarter to quarter and to
increase over the next several years as we augment our general and
administrative activities and resources to support increased expenditures on
preclinical and clinical trials and testing, and regulatory,
pre-commercialization and marketing activities.

Interest and Investment Income

Interest and investment income was $76,000 and $151,000 for the
three-month and six-month periods ended June 30, 2002, as compared to $221,000
and $484,000 for the

10



---



##### Table of Contents



corresponding periods in 2001. The decrease was due to lower average
invested cash balances and lower interest rates.

Interest and Investment Expense

Interest and investment expense was $90,000 and $181,000 for the
three-month and six-month periods ended June 30, 2002, as compared to $90,000
and $153,000 for the corresponding periods in 2001.

Other Income (Expense), net

Other income/(expense), net was $4,000 and $(13,000) for the three-month
and six-month periods ended June 30, 2002, as compared to $234,000 and $242,000
for the corresponding periods in 2001. The higher other income amount in 2001
was due to a repayment of a loan that we had previously
written off.

Liquidity and Capital Resources

At June 30, 2002 and 2001, we had $24,400,000 and $20,202,000,
respectively, in cash, cash equivalents and short-term investments, $633,000 of
which was restricted cash at each date. Our short-term investments consist
primarily of highly liquid marketable securities.

Net cash used by us in operating activities amounted to $2,571,000 for the
six-month period ended June 30, 2002. Net cash used in operating activities in
the 2002 period was less than our net loss for that period due to the receipt
of a payment from Sigma-Tau of $2,685,000 for a clinical trial collaboration
which increased deferred revenue balances by $2,461,000, increases in accrued
clinical trials expense and decreases in prepaid expenses, partially offset by
increases in accounts receivable and decreases in accrued compensation and
employee benefits.

Net cash used by us in investing activities amounted to $50,000 for the
six-month period ended June 30, 2002 and related primarily to the purchase of
$43,000 in property and equipment.

Net cash provided by financing activities amounted to $10,524,000 for the
six-month period ended June 30, 2002. Net cash provided by financing activities
consisted of $493,000 related to exercises of outstanding options under our
employee stock option plans, $72,000 for the issuance of common stock under our
employee stock purchase plan and gross proceeds of $10,630,000 from the
offering of our common stock, less $671,000 in financing-related costs.

Our contractual obligations and other commitments as of June 30, 2002 were
as follows:

|                                   |  |                        |            |      |  |             |           |           |  |               |           |  |  |   |           |  |  |   |   | 
|---------------------------------- |  | ---------------------- | ---------- | ---- |  | ----------- | --------- | --------- |  | ------------- | --------- |  |  | - | --------- |  |  | - | - | 
|                                   |  | Payments Due by Period
|                                   |  |                       
|Contractual                        |  |                        |            |      |  | Less than 1 |           |           |  |               |           |  |  |   |           |  |  |  
|Obligations                        |  | Total                  |            | year |  | 1-3 years   |           | 4-5 years |  | After 5 years
|                                   |  |                        |            |      |  |             |           |           |  |              
|Long Term Debt                     |  | $                      | 5,600,000  |      |  | $           |          |           |  | $             |          |  |  | $ | 5,600,000 |  |  | $ |  | 
|Operating Leases                   |  |                        | 5,312,000  |      |  |             | 1,330,000 |           |  |               | 2,695,000 |  |  |   | 1,287,000 |  |  |   |  | 
|                                   |  |                        |            |      |  |             |           |           |  |               |           |  |  |   |           |  |  |   |   | 
|Total Contractual Cash Obligations |  | $                      | 10,912,000 |      |  | $           | 1,330,000 |           |  | $             | 2,695,000 |  |  | $ | 6,887,000 |  |  | $ |  | 
|                                   |  |                        |            |      |  |             |           |           |  |               |           |  |  |   |           |  |  |   |   | 

11



---



##### Table of Contents



|                 |  |               |         |             |  |                                            |         |           |  |               |   |  |  |  |   |  |  |  |   | 
|---------------- |  | ------------- | ------- | ----------- |  | ------------------------------------------ | ------- | --------- |  | ------------- | - |  |  |  | - |  |  |  | - | 
|                 |  |               |         |             |  | Amount of Commitment Expiration Per Period
|                 |  |               |         |             |  |                                           
|Other Commercial |  | Total Amounts |         | Less than 1 |  |                                            |         |           |  |               |   |  |  |  |   | 
|Commitments      |  | Committed     |         | year        |  | 1-3 years                                  |         | 4-5 years |  | After 5 years
|                 |  |               |         |             |  |                                            |         |           |  |              
|Letter of Credit |  | $             | 633,000 |             |  | $                                          | 633,000 |           |  |               |  |  |  |  |  |  |  |  |  | 

None of our officers or directors were involved in any related party
transactions with the Company in the three-month and six-month periods ended
June 30, 2002.

Management intends to give priority use of the Companys financial
resources to ZADAXIN clinical programs in the United States. Management
believes our existing capital resources and interest on funds available are
adequate to maintain our current and planned operations through 2003. We will
need to obtain additional capital to support our long-term product development.
Assuming approval of ZADAXIN by the U.S. FDA and other regulatory authorities,
we may also require additional capital for our commercialization programs. The
need, timing and amount of additional funding will depend upon numerous
factors, including the level of ZADAXIN sales, the timing and amount of
manufacturing costs related to ZADAXIN and CPX, the availability of
complementary products, technologies and businesses, the initiation and
continuation of preclinical and clinical trials and testing, particularly
ZADAXIN trials in the U.S. and Japan, the timing of regulatory approvals,
developments in relationships with existing or future collaborative parties and
the status of competitive products. In the event we need to raise additional
financing, the unavailability or the inopportune timing of any financing could
prevent or delay our long-term product development and commercialization
programs, either of which would severely hurt our business.

Risk Factors

You should carefully consider the risks described below, in addition to
the other information in this report on Form 10-Q, before making an investment
decision. Each of these risk factors could adversely affect our business,
financial condition, and operating results as well as adversely affect the
value of an investment in our common stock.

Our phase 3 program in the U.S. for the approval of ZADAXIN in combination with
pegylated interferon for the treatment of hepatitis C may fail, which will harm
our business.

We designed a phase 3 study program based on the use of ZADAXIN in
combination with pegylated interferon. There can be no assurances that the
results from our previous phase 2 and phase 3 hepatitis C studies which enabled
us to produce this design will carryover to the trials involving a combination
of ZADAXIN and pegylated interferon and any resulting data may be insufficient
or inadequate to demonstrate appropriate efficacy under FDA guidelines. In
addition, insufficient data resulting from the studies would also
adversely affect our ability to market and sell ZADAXIN in markets where it is
approved for sale. We manufacture the ZADAXIN used in our phase 3 trials under
cGMP guidelines and under our direct manufacturing and quality control using
third party cGMP manufacturers and suppliers. If unanticipated deficiencies in
these manufacturers or suppliers occur, this could create a delay in the
assembling of a timely and acceptable new drug application (NDA). We have begun
enrolling patients in both of the phase 3 trials in our hepatitis C clinical
program; however, we may not be able to enroll patients quickly enough to meet
our timing expectations for completing the trial which

12



---



##### Table of Contents



would delay the preparation of an NDA; or we may not be able to fully
enroll the studies which could weaken the quality of an NDA. Our hepatitis C
clinical trials have been designed to show that the combination of ZADAXIN and
pegylated interferon adds a significant clinical benefit when compared to the
use of pegylated interferon alone in the treatment of hepatitis C. However, the
independent use of the pegylated form of interferon may perform better than
anticipated which could weaken the quality of an NDA. If any of the foregoing
occurs, our efforts to market and sell ZADAXIN in combination with pegylated
interferon will be impaired, and our business will suffer.

The pegylated interferon we will use in our phase 3 program in the U.S.
has not yet been approved by the FDA. If this pegylated interferon is not
approved by the FDA, we would need to conduct an additional trial with an
approved form, resulting in additional delays and expenses.

We may not be able to successfully develop or commercialize our products.

Many of our products are in the development stage and will require the
commitment of substantial resources, devoted to extensive research,
development, preclinical testing, clinical trials, manufacturing scale-up and
regulatory approval prior to being ready for sale. We cannot assure you that
commercially viable products will result from these efforts. We face
significant technological risks inherent in developing these products. We may
also abandon some or all of our proposed products before they become
commercially viable. We have limited experience in conducting and managing U.S.
clinical trials and we rely, in part, on third parties, particularly clinical
research organizations and our development partners, to assist us in managing
and monitoring clinical trials. Our reliance on these third parties may result
in delays in completing, or failure to complete, these clinical trials if third
parties fail to perform their obligations to us. If any of our products, even
if developed and approved, cannot be successfully commercialized in a timely
manner, our business will be harmed and the price of our stock may decline.

We have not yet sold any product other than ZADAXIN. We have experienced
difficulties with the formulation of CPX which has delayed its further
development. Our future revenue growth depends on increased market acceptance
and commercialization of ZADAXIN in additional countries, particularly in the
U.S., Europe and Japan. If we fail to successfully market ZADAXIN, or if we
cannot commercialize this drug in the U.S. and other additional markets, our
revenue and operating results will suffer. Our future revenue will also depend
in part on our ability to develop other commercially viable and accepted
products; however, until we obtain additional resources, substantially all of
our resources are focused on the development of ZADAXIN. Market acceptance of
our products will depend on many factors, including our ability to convince
prospective customers and prospective strategic partners that our products are
an attractive alternative to other treatments and therapies, and manufacture
products in sufficient quantities with acceptable quality and at an acceptable
cost. Failure to do so will hurt our operations.

If we fail to satisfy and comply with governmental regulations or if government
regulations change, our business may suffer.

All new drugs, including our products, which have been developed or are
under development, are subject to extensive and rigorous regulation by the FDA,
and comparable

13



---



##### Table of Contents



agencies in state and local jurisdictions and in foreign countries. These
regulations govern, among other things, the development, testing,
manufacturing, labeling, storage, pre-market approval, importation,
advertising, promotion, sale and distribution of our products. These
regulations change from time to time and new regulations may be adopted. For
example, in prior years, legislation has been introduced in the U.S. Congress
that would restrict the duration of the marketing exclusivity of an orphan
drug. There can be no assurances that this type of legislation will not be
reintroduced and passed into law, or that the benefits of the existing statute
will remain in effect. Our failure to satisfy and comply with regulations
adopted by the FDA, and comparable agencies in state and local jurisdictions
and in foreign countries, may delay or stop approval of our drugs. In
particular, such failure can, among other things, result in warning letters,
fines, suspensions of regulatory approvals, product recalls or seizures,
operating restrictions, injunctions, total or partial suspension of production,
civil penalties, and criminal prosecutions. Furthermore, additional government
regulation may be established or imposed by legislation or otherwise, which
could prevent or delay regulatory approval of ZADAXIN or any of our other
future products. Adverse events related to our products in any of our existing
or future markets could cause regulatory authorities to withdraw market
approval for such products, if any, or prevent us from receiving market
approval in the future. There is no assurance that ZADAXIN, or any of our other
products, will demonstrate efficacy sufficient to obtain approval by the FDA or
its counterpart regulatory agencies in other countries.

Satisfaction of government regulations may take several years and the time
needed to satisfy them varies substantially, based on the type, complexity and
novelty of the pharmaceutical product. As a result, government regulation may
cause us to delay the introduction of, or prevent us from marketing, our
existing or potential products for a considerable period of time and to impose
costly procedures upon our activities. If regulatory approval of our products
is granted, such approval may impose limitations on the indicated uses for
which our products may be marketed.

If we fail to obtain regulatory approvals for our products in countries where
we have targeted regulatory approval, we may not be able to sustain or increase
our revenues and our stock price may decline.

The research, preclinical and clinical development, manufacturing,
marketing and sale of ZADAXIN and our other drug candidates are subject to
extensive regulation by governmental authorities. ZADAXIN and any other
products we may sell in countries outside the U.S. must be approved by the
foreign counterparts of the FDA before they can be sold in any jurisdiction.
Obtaining regulatory approval is time-consuming and expensive. In some
countries where we are contemplating marketing and selling ZADAXIN, the
regulatory approval process for drugs that have not been previously approved in
countries with established clinical trial review procedures is uncertain, and
this may delay or prevent the grant of regulatory approvals for ZADAXIN. In
addition, to secure these regulatory approvals, we will need, among other
things, to demonstrate favorable results from additional clinical trials of
ZADAXIN and the safety and efficacy of CPX as a treatment for cystic fibrosis
in preclinical and clinical trials. Even if we are able to complete the
clinical trials we have sponsored or are planning in a timely or cost effective
manner, these trials may not fulfill the applicable regulatory approval
criteria, in which case we will not be able to obtain regulatory approval in
these countries. There can be no assurance that we will ultimately obtain
regulatory approvals in our targeted countries in a timely and cost-effective

14



---



##### Table of Contents



manner or at all. Our failure to obtain the required regulatory approvals
so that we can develop, market and sell our products in countries where we
currently do not have such rights will limit our revenues.

In addition, adverse results that occur in our clinical trials could
result in restrictions on the use of ZADAXIN, which may also hurt our business.

We will need to obtain additional capital to support our long-term product
development and commercialization programs.

Our ability to achieve and sustain operating profitability depends in
large part on our ability to commence, execute and complete clinical programs
for, and obtain additional regulatory approvals for ZADAXIN and other drug
candidates, particularly in the U.S., Europe and Japan, increase ZADAXIN sales
in existing markets, and launch ZADAXIN in new markets. We cannot assure you
that we will ever achieve more significant levels of sales or that we will
receive additional ZADAXIN market approvals.

Our current sales levels of ZADAXIN are not expected to generate all the
funds we anticipate will be needed to support our current plans for product
development including our U.S. phase 3 clinical trials for ZADAXIN. We will
need to obtain additional financing to support our product development and
commercialization programs. We may seek additional funds through public and
private stock offerings, arrangements with corporate partners, borrowings under
lease lines of credit or other sources. If we cannot raise the necessary funds,
we will have to reduce our capital expenditures, curtail or delay our phase 3
clinical trials, scale back our development of new products, reduce our
workforce and out-license to others products or technologies that we otherwise
would seek to commercialize ourselves, any of which may harm our business and
cause our stock price to fall.

The amount of capital we will need will depend on many factors, including:
the timing, location, scope and results of ongoing and planned preclinical
studies and clinical trials; the cost of manufacturing or obtaining preclinical
and clinical materials; the timing and cost involved in applying for and
obtaining FDA and international regulatory approvals; whether we elect to
establish additional partnering arrangements for development, sales,
manufacturing, and marketing of our products; the level of future ZADAXIN
sales; expense levels for our international sales and marketing efforts; our
ability to establish and maintain strategic arrangements for development,
sales, manufacturing and marketing of our products; competing technological and
market developments; the costs involved in filing, prosecuting and enforcing
patent claims; whether any or all of our outstanding convertible notes are
converted to common stock; and whether any or all of our outstanding common
stock warrants are exercised and the timing and amount of these exercises.

Many of the foregoing factors are not within our control. If we need to
raise additional funds and such funds are not available on reasonable terms, we
may be required to delay or cancel our product development and
commercialization programs. Any additional equity financing will be dilutive to
shareholders, and any debt financing, if available, may include restrictive
covenants.

15



---



##### Table of Contents



We have a history of operating losses and an accumulated deficit. We expect to
continue to incur losses in the near term and may never achieve profitability.

We have experienced significant operating losses since our inception and
as of June 30, 2002, we had an accumulated deficit of approximately $129
million. We expect our operating expenses to increase over the next several
years as we plan to dedicate substantially all of our resources to expanding
our development, testing and marketing capabilities, particularly in the U.S.,
and we may never achieve profitability. Our failure to achieve profitability
may cause our stock price to decline.

We are dependent on the sale of ZADAXIN in foreign countries, particularly
China, and if we experience difficulties in our foreign sales efforts, our
financial condition will be harmed.

Our financial condition in the near term is highly dependent on the sale
of ZADAXIN in foreign countries. If we experience difficulties in our foreign
sales efforts, our business will suffer and our financial condition will be
harmed. Substantially all of our ZADAXIN sales are to customers in the Peoples
Republic of China. Sales of ZADAXIN in China may be limited due to its low
average personal income, lack of patient cost reimbursement, poorly developed
infrastructure, and existing and potential competition from other products,
possibly including generics.

In addition, our ZADAXIN sales and operations in other parts of Asia, as
well as in Latin America and the Middle East, are subject to a number of risks,
including: difficulties and delays in obtaining pricing approvals and
reimbursement, product health registrations and importation permits; unexpected
changes in regulatory requirements; difficulties in staffing and managing
foreign operations; long payment cycles; difficulties in accounts receivable
collection; difficulties in enforcing our proprietary rights; currency
fluctuations; adverse or deteriorating economic conditions; and potential
adverse tax consequences.

We do not have product sales in the U.S. with which to offset any decrease
in our revenue from ZADAXIN sales in Asia, Latin America and the Middle East.
In addition, some countries in these regions, including China, regulate
pharmaceutical prices and pharmaceutical importation. These regulations may
reduce prices for ZADAXIN to levels significantly below those that would
prevail in an unregulated market, limit the volume of product which may be
imported and sold, or place high import duties on the product, any of which may
limit the growth of our revenues or cause them to decline.

Because of Chinas tiered method of importing and distributing finished
pharmaceutical products, our quarterly results may vary substantially from one
period to the next.

China uses a tiered method to import and distribute finished
pharmaceutical products. At each port of entry, and prior to moving the product
forward to the distributors, government licensed importing agents must process
and evaluate each shipment to determine whether such shipment satisfies Chinas
quality assurance requirements. In order to efficiently manage this process,
the importing agents place relatively few orders from time to time over any six
month period and each order is typically for large quantities. Therefore, our
sales to an importing agent

16



---



##### Table of Contents



can vary substantially from quarter to quarter depending on the size and
timing of the orders, which has in the past and may in the future cause our
quarterly results to fluctuate. Because we use four importing agents in China,
our account receivable from any one importing agent is material and if we were
unable to collect receivables from any importer, our business and cash-flow
would be adversely affected, at least in the short term.

We have limited sales, marketing and distribution capabilities, which may
adversely affect our ability to successfully commercialize our products.

We currently have limited sales, marketing and distribution capabilities,
and we anticipate that we will be relying on third-party collaborators to sell,
market and distribute our products for the foreseeable future. If our
arrangements with these third parties are not successful, or if we are unable
to enter into additional third-party arrangements, we may need to substantially
expand our sales, marketing and distribution force. Our efforts to expand may
not succeed, or we may lack sufficient resources to expand in a timely manner,
either of which will harm our operating results. In addition, if we are able to
further expand our sales, marketing and distribution capabilities, we will
begin competing with other companies that have experienced and well funded
operations. If we cannot successfully compete with these larger companies, our
revenues may not grow and our business may suffer.

If we are not able to establish and maintain adequate manufacturing and supply
relationships, the development and sale of our products could be impaired.

To be successful, our products must be manufactured in commercial
quantities, in compliance with regulatory requirements and at an acceptable
cost. We may not be able to maintain the long-term manufacturing relationships
we currently have with our suppliers and we anticipate changes will be needed
if our volume requirements increase. Manufacturing interruptions could
significantly delay clinical development of potential products and reduce
third-party or clinical researcher interest and support of proposed trials.
These interruptions could also impede commercialization of our products,
including sales of ZADAXIN in approved markets, and impair our competitive
position. Any of these developments would harm our business.

In some countries, a manufacturing change may require additional
regulatory approvals. If we do not obtain the required regulatory approvals for
a manufacturing change in a timely fashion, new ZADAXIN marketing approvals may
be delayed or sales may be interrupted until the manufacturing change is
approved. Either of these results would harm our business.

In addition, manufacturing, supply and quality control problems may arise
as we, either alone or with subcontractors, attempt to scale-up our
manufacturing procedures. We may not be able to scale-up in a timely manner or
at a commercially reasonable cost, either of which could cause delays or pose a
threat to the ultimate commercialization of our products and harm our business.

If we do not obtain rights to additional products from third parties, our
prospects for future revenue may decline.

17



---



##### Table of Contents



We are only actively pursuing clinical development of ZADAXIN at this
time. If we do not devote additional resources to CPX or advance SCV-07 and
DAX, the other products to which we have in-licensed rights, from preclinical
into clinical development, we may lose the rights to these products. We may
also have a shortage of drugs to develop and commercialize if we do not license
or otherwise acquire rights to additional drugs. Any shortage in the number of
drugs that we are able to develop and commercialize may reduce our prospects
for future revenue.

Commercialization of some of our products depends on collaborations with
others. If our collaborators are not successful, or if we are unable to find
future collaborators, we may not be able to properly develop and commercialize
our products.

We depend in part on our distributors and business partners to develop
and/or promote our drugs, and if they are not successful in their efforts or
fail to do so, our business will suffer. We generally do not have control over
the amount and timing of resources that our business partners devote to ZADAXIN
and they have not always performed as or when expected. If they do not perform
their obligations as we expect, particularly obligations regarding clinical
trials, our development expenses would increase and the development and/or sale
of our products could be limited or delayed, which could hurt our business and
cause our stock price to decline. In addition, our relationships with these
companies may not be successful. Disputes may arise over ownership rights to
intellectual property, know-how or technologies developed with our
collaborators, and we may not be able to negotiate similar additional
arrangements in the future to develop and commercialize ZADAXIN or other
products.

If we fail to protect our products, technologies and trade secrets, we may not
be able to successfully use, manufacture, market or sell our products, or we
may fail to advance or maintain our competitive position.

Our success depends significantly on our ability to obtain and maintain
meaningful patent protection for our products and technologies, to preserve our
trade secrets and to avoid infringing on the proprietary rights of third
parties. Our pending patent applications may not result in the issuance of
patents in the future. Our patents or patent applications may not have priority
over others applications. Our existing patents and additional patents, if any,
that issued, may not provide a competitive advantage to us or may be
invalidated or circumvented by our competitors. Others may independently
develop similar products or design around patents issued or licensed to us.
Patents issued to, or patent applications filed by, other companies could harm
our ability to use, manufacture, market or sell our products or maintain our
competitive position with respect to our products. Many of our patents relating
to ZADAXIN have expired, and we have rights to other patents and patent
applications relating to ZADAXIN under exclusive licenses. If we breach the
terms of any of these licenses, we could lose our rights to these patents and
patent applications.

Our commercial success also depends in part on us not infringing valid,
enforceable patents or proprietary rights of third parties, and not breaching
any licenses that may relate to our technologies and products. We are aware of
third-party patents that may relate to our products. It is possible that we may
unintentionally infringe these patents or other patents or proprietary rights
of third parties. We may in the future receive notices claiming infringement
from third

18



---



##### Table of Contents



parties as well as invitations to take licenses under third-party patents.
Any legal action against us or our collaborative partners claiming damages and
seeking to enjoin commercial activities relating to our products and processes
affected by third-party rights may require us or our collaborative partners to
obtain licenses in order to continue to manufacture or market the affected
products and processes. Our efforts to defend against any of these claims, even
if unmeritorious, would require us to devote resources and attention that could
have been directed to our operations and growth plans. In addition, these
actions may subject us to potential liability for damages. We or our
collaborative partners may not prevail in a patent action and any license
required under a patent may not be made available on commercially acceptable
terms, or at all.

Pharmaceuticals are either not patentable or have only recently become
patentable in some of the countries in which we have exclusive rights to
ZADAXIN. Past enforcement of intellectual property rights in many of these
countries has been limited or non-existent. Future enforcement of patents and
proprietary rights in many other countries will likely be problematic or
unpredictable. Moreover, the issuance of a patent in one country does not
assure the issuance of a similar patent in another country. Claim
interpretation and infringement laws vary by nation, so the extent of any
patent protection is uncertain and may vary in different jurisdictions.

If we make any acquisitions, we will incur a variety of costs and may never
realize the anticipated benefits.

If appropriate opportunities become available, we may attempt to acquire
products, product candidates or businesses that we believe fit strategically
with our business. We currently have no commitments or agreements with respect
to material acquisitions. If we do undertake any transaction of this sort, the
process of integrating an acquired product, product candidate or business may
result in operating difficulties and expenditures and may absorb significant
management attention that would otherwise be available for our ongoing business
development plans. Moreover, we may never realize the anticipated benefits of
any acquisition. Future acquisitions could result in in-process research and
development expenses, potentially dilutive issuances of equity securities, the
incurrence of debt, contingent liabilities and/or amortization or impairment of
goodwill or other intangible assets, which could adversely affect our business,
financial condition and results of operations.

We may lose market share or otherwise fail to compete effectively in the
intensely competitive biopharmaceutical industry.

Competition in the biopharmaceutical industry is intense and we expect
that competition to increase. Our success depends on our ability to compete. We
believe that the principal competitive factors in this industry include the
efficacy, safety, price, therapeutic regimen, manufacturing quality assurance,
and patents associated with a given drug. Our competitors include
biopharmaceutical companies, biotechnology firms, universities and other
research institutions, both in the U.S. and abroad, that are actively engaged
in research and development of products in the therapeutic areas we are
pursuing, particularly hepatitis C, hepatitis B, cancer, and cystic fibrosis.
Competitors are currently marketing drugs for hepatitis C, hepatitis B and
cancer, or have products in late-stage clinical trials.

19



---



##### Table of Contents



Most of our competitors, particularly large biopharmaceutical companies,
have substantially greater financial, technical, regulatory, manufacturing,
marketing and human resource capabilities than we do. Most of them also have
extensive experience in undertaking the preclinical and clinical testing and in
obtaining the regulatory approvals necessary to market drugs. Additional
mergers and acquisitions in the pharmaceutical industry may result in even more
resources being concentrated with our competitors. Where comparable products
are marketed by other companies, price is a competitive factor. Increased
competitive pressure could lead to intensified price-based competition
resulting in lower prices and margins, which would hurt our operating results.

We currently rely on sales of ZADAXIN outside of the U.S. as a treatment
for hepatitis C and hepatitis B and certain cancers as our primary source of
product revenue. Several large biopharmaceutical companies have substantial
commitments to alpha interferon, an approved drug for treating hepatitis B and
hepatitis C, and to lamivudine, an approved drug to treat hepatitis B. We
cannot assure you that we will compete successfully against our competitors or
that our competitors, or potential competitors, will not develop drugs or other
treatments for hepatitis C, hepatitis B, cystic fibrosis, cancer and other
diseases that will be superior to ours.

In the U.S., our product ZADAXIN is being evaluated in combination with
pegylated interferon for the treatment of hepatitis C. Other companies are
researching, developing, or marketing other products for use in combination
with pegylated interferons for clinical indications including HCV and HBV.
Such competitive products include ribavirin, allegedly improved ribavirin
molecules and other products not yet in late stage clinical trials such as
therapeutic vaccines and reverse transcriptase inhibitors. Our clinical trials
may not show ZADAXIN to have advantages over such existing or future
competitive products.

We believe that we can position ZADAXIN as a complementary rather than
competitive drug to many therapies, but cannot guarantee that we will be
successful in this endeavor. We expect continuing advancements in and
increasing awareness of the use of immune system enhancer therapy to fight
cancer and infectious diseases and that this development may create new
competitors. We cannot assure you that we will be able to successfully compete
with any such competitors.

Legislative actions, higher insurance cost and potential new accounting
pronouncements are likely to impact our future financial position and results
of operations.

There have been regulatory changes, including the Sarbanes-Oxley Act, and there
may be potential new accounting pronouncements or regulatory rulings, which will
have an impact on our future financial position and results of operations. The
Sarbanes-Oxley Act and other rule changes and proposed legislative initiatives
following the Enron bankruptcy are likely to increase general and
administrative costs. In addition, insurers are likely to increase rates as a
result of high claims rates over the past year and our rates for our various
insurance policies are likely to increase. Further, proposed initiatives could
result in changes in accounting rules, including legislative and other
proposals to account for employee stock options as an expense. These and other
potential changes could materially increase the expenses we report under
generally accepted accounting principles, and adversely affect our operating
results.

20



---



##### Table of Contents



If third-party reimbursement is not available or patients cannot otherwise pay
for ZADAXIN, we may not be able to successfully market ZADAXIN.

Our ability to successfully commercialize our products may depend in part
on the extent to which coverage and reimbursement to patients for our products
will be available from government health care programs, private health insurers
and other third party payors or organizations. Significant uncertainty exists
as to the reimbursement status of new therapeutic products, such as ZADAXIN,
and we cannot assure you that third party insurance coverage and reimbursement
will be available for therapeutic products we might develop. In most of the
emerging markets in which we sell ZADAXIN or intend to sell ZADAXIN,
reimbursement for ZADAXIN under government or private health insurance programs
is not yet widely available. The failure to obtain third-party reimbursement
for our products, particularly in the U.S., Europe and Japan, will harm our
business. In the U.S., proposed health care reforms could limit the amount of
third-party reimbursement available for our products. We cannot assure you that
additional limitations will not be imposed in the future on drug coverage and
reimbursement. In many emerging markets where we have marketing rights to
ZADAXIN, government resources and per capita income may be so low that our
products will be prohibitively expensive. In these countries, we may not be
able to market our products on economically favorable terms, if at all.

Efforts by governmental and third-party payors to contain or reduce health
care costs could cause us to reduce the prices at which we market our drugs,
which will reduce our gross margins and may harm our business. Various
governments and third-party payors are trying to contain or reduce the costs of
health care through various means. We expect that there will continue to be a
number of legislative proposals to implement government controls. The
announcement of proposals or reforms could cause us to reduce the prices at
which we market our drugs, which will reduce our gross margins and may harm our
business.

If the current economic slowdown in the U.S. causes the economies of other
countries, particularly those in Asia, Latin America and the Middle East to
experience a slowdown or recession, our business will suffer.

The U.S. is the worlds largest consumer and as such, the current economic
slowdown in the U.S. may adversely affect the economies of other countries,
including the developing countries in Asia, Latin America and the Middle East
from which we derive all of our revenues. If the economic conditions in the
U.S. continue or worsen, these developing countries may also experience an
economic slowdown or recession, which would likely result in a decrease of
sales of ZADAXIN. Any decrease in sales of ZADAXIN would harm our operating
results, delay our efforts to achieve profitability, and likely cause our stock
price to decline.

If we lose key personnel or are unable to attract and retain additional, highly
skilled personnel required for the expansion of our activities, our business
will suffer.

We are highly dependent upon our ability to attract and retain qualified
personnel because of the specialized, scientific and international nature of
our business. There is intense competition for qualified management, scientific
and technical personnel in the pharmaceutical industry, and we may not be able
to attract and retain the qualified personnel we need to grow and develop our
business globally. In addition, numerous key responsibilities at SciClone are

21



---



##### Table of Contents



assigned to a small number of individuals. If we are unable to attract and
retain qualified personnel as needed or promptly replace those employees who
are critical to our product development and commercialization, the development
and commercialization of our products would adversely be affected. At this
time, we do not maintain key person life insurance on any of our key
personnel.

We may be subject to product liability lawsuits and our insurance may be
inadequate to cover damages.

Clinical trials or marketing of any of our current and potential products
may expose us to liability claims from the use of these products. We currently
carry product liability insurance. However, we cannot be certain that we will
be able to maintain insurance on acceptable terms for clinical and commercial
activities or that the insurance would be sufficient to cover any potential
product liability claim or recall. If we fail to have sufficient coverage, our
business, results of operations and cash flows could be adversely affected.

If we are unable to comply with environmental laws and regulations, our
business may be harmed.

We are subject to federal, state and local laws and regulations governing
the use, manufacture, storage, handling and disposal of hazardous materials and
waste products. We currently maintain a supply of hazardous materials at our
facilities. In the event of an accident, we could be liable for any damages
that result, and the liability could exceed our resources. While we outsource
our research and development programs involving the controlled use of
biohazardous materials, if in the future we conduct these programs ourselves,
we might be required to incur significant cost to comply with the environmental
laws and regulations.

The price of our common stock has experienced substantial volatility and may
fluctuate due to factors beyond our control.

As a result of the September 11, 2001 events in Pennsylvania, New York
City and Washington, D.C., U.S. and global economies have weakened, which may
result in a decrease in our revenues and cause our stock price to decline.
Further, high profile corporate governance and accounting problems and
resulting corporate failures have eroded investor confidence. In the wake of
these events, U.S. and global capital markets have experienced a period of
extreme volatility, and this may continue for some time.

In addition, there has been significant volatility in the market prices
for publicly traded shares of pharmaceutical and biotechnology companies,
including ours. The following factors may have an adverse impact on the market
price of our common stock: significant negative changes in the major equity
market indices; announcements of technical or product developments by us or our
competitors; governmental regulation; health care legislation; public
announcements regarding advances in the treatment of the disease states that we
are targeting; public announcements from government officials relating to the
biotechnology or pharmaceutical industries; patent or proprietary rights
developments; changes in third-party reimbursement policies for our products;
and fluctuations in our operating results. We cannot assure you that the
price of our common stock will remain at or exceed current levels.

22



---



##### Table of Contents



If the current war on terrorism causes economic slowdowns in the economies of
certain countries our business will suffer.

The United States and its allied nations are aggressively attacking
terrorism with military and economic actions. If these actions lead to economic
slowdowns in the economies of developing countries in Asia, Latin America and
the Middle East from which we currently derive all of our product revenue, then
our sales could decrease. Any decrease in sales would harm our operating
results, delay our efforts to achieve profitability, and likely cause our stock
price to decline.

Our indebtedness may result in future liquidity problems.

As of June 30, 2002, we had $5.6 million in convertible notes payable, of
which $4.0 million were issued in the quarter ended December 31, 2000 and $1.6
million were issued in the quarter ended March 31, 2001. This indebtedness, or
additional debt we may incur to fund our operations, may make it more difficult
for us to obtain additional financing. The outstanding notes are payable five
years after issuance unless converted into common stock at the sole discretion
of the holder. If we are unable to satisfy our debt service requirements,
substantial liquidity problems could result which would negatively impact our
future prospects. As of June 30, 2002 we had cash, cash equivalents and
short-term investments of $24.4 million.

Substantial sales of our stock or convertible securities may impact the market
price of our common stock.

As of June 30, 2002, stock options for 5,141,095 shares of common stock
were outstanding, of which options for 3,457,942 shares were exercisable. Also
outstanding as of the same date were warrants exercisable for 1,970,500 shares
of common stock and two issues of notes convertible into a total of 684,140
shares of common stock. In addition, the note holder has the right to purchase
senior unsecured convertible notes due December 2005 and March 2006. If issued,
the additional notes will bear no interest (zero coupon) and will be
convertible into 684,140 shares of our common stock. Upon exercise of options
or warrants, or conversion of the notes, these issued shares of common stock
will be freely tradable.

Future sales of substantial amounts of our common stock could adversely
affect the market price of our common stock. Similarly, if we raise additional
funds through the issuance of common stock or securities convertible into or
exercisable for common stock, the percentage ownership of our shareholders will
be reduced and the price of our common stock may fall.

Issuing preferred stock with rights senior to those of our common stock could
adversely affect holders of common stock.

Our charter documents give our board of directors the authority to issue
additional series of preferred stock without a vote or action by our
shareholders. The board also has the authority to determine the terms of
preferred stock, including price, preferences and voting rights. The rights of
holders of our common stock may be adversely affected by the rights granted to
holders of preferred stock. For example, a series of preferred stock may be
granted the right to receive a

23



---



##### Table of Contents



liquidation preference  a pre-set distribution in the event of a
liquidation  that would reduce the amount available for distribution to
holders of common stock. In addition, the issuance of preferred stock could
make it more difficult for a third party to acquire a majority of our
outstanding voting stock. As a result, common shareholders could be prevented
from participating in transactions that would offer an optimal price for their
shares.




Item 3. Quantitative and Qualitative Disclosures About Market Risk.

The primary objective of our investment activities is to preserve
principal while at the same time maximizing yields without significantly
increasing risk. To achieve this objective, we invest in highly liquid and
high quality debt securities. Our investments in debt securities are subject
to interest rate risk. To minimize the exposure due to an adverse shift in
interest rates, we invest in short term securities and maintain an average
maturity of less than one year. A hypothetical 60 basis point increase in
interest rates would result in an approximate $82,469 decrease (0.6%) in fair
value of our available-for-sale securities.

The potential change noted above is based on sensitivity analyses
performed on our financial positions at June 30, 2002. Actual results may
differ materially.

24



---



##### Table of Contents






PART II. OTHER INFORMATION




Item 4. Submission of Matters to a Vote of Security Holders

We held our Annual Meeting of Shareholders on May 30, 2002 to elect seven
(7) directors, to appoint Ernst & Young LLP as independent auditors, to
reincorporate the Company as a Delaware corporation, to increase the number of
shares which may be issued under the 1995 Equity Incentive Plan, and to amend
the 1995 Nonemployee Director Stock Option Plan.

At the Annual Meeting of Shareholders, all of the director
nominees were elected with voting as follows:

|                      |  |     |            |          |  |  |           | 
|--------------------- |  | --- | ---------- | -------- |  |  | --------- | 
|                      |  |     |            | Votes    |  |  |          
|                      |  | For |            | Withheld
|                      |  |     |            |         
|Jere E. Goyan, Ph.D.  |  |     | 23,406,994 |          |  |  | 2,973,092 | 
|Donald R. Sellers     |  |     | 22,985,653 |          |  |  | 3,394,433 | 
|John D. Baxter, M.D.  |  |     | 23,480,707 |          |  |  | 2,899,379 | 
|Edwin C. Cadman, M.D. |  |     | 23,415,769 |          |  |  | 2,964,317 | 
|Rolf H. Henel         |  |     | 23,472,154 |          |  |  | 2,907,932 | 
|Jon S. Saxe           |  |     | 23,416,154 |          |  |  | 2,963,932 | 
|Dean S. Woodman       |  |     | 23,456,794 |          |  |  | 2,923,292 | 

Shareholders ratified the appointment of Ernst & Young LLP as independent
auditors for the Company for the fiscal year ending December 31, 2002. Voting
was as follows: 26,205,890 for; 122,321, against; and 51,874 abstaining.

Although a majority of the votes cast were in favor of the proposals to
reincorporate SciClone Pharmaceuticals as a Delaware corporation and the
associated initiatives, these proposals did not receive the number of votes
required for approval. Voting was as follows: 10,082,695 for; 4,030,672
against; and 152,601 abstaining.

Shareholders approved the increase in the maximum aggregate number of shares of
Common Stock that may be issued under the Companys 1995 Equity Incentive Plan
by 1,350,000 shares from 4,750,000 shares to 6,100,000 shares. Voting was as
follows: 20,552,637 for; 5,640,386 against; and 187,063 abstaining.

Shareholders approved amending the Companys 1995 Nonemployee Director Stock
Option Plan to (1) increase the maximum aggregate number of shares of Common
Stock that may be issued under the Plan by 250,000 shares, from 500,000 shares
to 750,000 shares (2) increase the regular annual grant by 10,000 shares, from
10,000 to 20,000 shares, and (3) provide for full acceleration of vesting and
exercisability of options to purchase Common Stock granted under the Plan upon
the occurrence of a change in control. Voting was as follows: 20,917,204 for;
5,154,206 against; and 308,676 abstaining.

25



---



##### Table of Contents






Item 6. Exhibits and Reports on Form 8-K



|(a) |  | Exhibits
|--- |  | --------

|     |  |                                         
|---- |  | ----------------------------------------
|99.1 |  | Certification of Chief Executive Officer
|    
|99.2 |  | Certification of Chief Financial Officer



|(b) |  | Reports on Form 8-K
|--- |  | -------------------
|   
|    |  | None.              

26



---



##### Table of Contents






SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.



| | SCICLONE PHARMACEUTICALS, INC.
(Registrant)
| | -------------------------------------------

|                      |  |                                                                                      
|--------------------- |  | -------------------------------------------------------------------------------------
|Date: August 14, 2002 |  | /s/ Richard A. Waldron                                                               
|                      |  |                                                                                      
|                      |  | Richard A. Waldron
Chief Financial Officer
(Principal Financial & Accounting Officer)

27